Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins
about
Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesisNK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyInsights into cytokine-receptor interactions from cytokine engineeringCrystal Structure of the interleukin-15.interleukin-15 receptor alpha complex: insights into trans and cis presentationEnergy-sensing factors coactivator peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonistLoss of IL-15 receptor α alters the endurance, fatigability, and metabolic characteristics of mouse fast skeletal muscles.Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma.Novel human interleukin-15 agonistsSerum and muscle interleukin-15 levels decrease in aging mice: correlation with declines in soluble interleukin-15 receptor alpha expressionIntravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines.Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cellsHighly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cisLiver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapyGD2-targeted immunotherapy and radioimmunotherapyInterleukin-15:Interleukin-15 receptor α scaffold for creation of multivalent targeted immune moleculesConverting IL-15 to a superagonist by binding to soluble IL-15R{alpha}Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans.IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo.Mechanistic model of natural killer cell proliferative response to IL-15 receptor stimulationRole of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy.Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses.MHC class I and TCR avidity control the CD8 T cell response to IL-15/IL-15Rα complex.Differential expression of pro-inflammatory cytokines IL-15Ralpha, IL-15, IL-6 and TNFalpha in synovial fluid from rheumatoid arthritis patients.IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization.IL-15, in synergy with RAE-1ɛ, stimulates TCR-independent proliferation and activation of CD8(+) T cells.Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum.Skeletal muscle interleukin 15 promotes CD8(+) T-cell function and autoimmune myositis.Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo.IL-15Rα is a determinant of muscle fuel utilization, and its loss protects against obesity.Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanismParacrine and transpresentation functions of IL-15 are mediated by diverse splice versions of IL-15Rα in human monocytes and dendritic cellsThe interleukin-15/interleukin-15 receptor system as a model for juxtacrine and reverse signaling.Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal ModelsDesign and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptorIL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation.
P2860
Q24301975-242ADC49-8568-4D24-84BE-78DEEEE4A46DQ24604346-39A0961A-5734-4BE5-9AF5-C9A81C707262Q26797345-7E8E1F7A-473E-474D-9072-8ECDCFEAB174Q26852703-D0270348-E1AD-4271-BE31-1D371E6F76B7Q27648832-C65810FD-D1A5-4902-B9D5-919ECCEC6DF3Q28569816-B5EED5FE-ED7A-445B-8BB0-4F329DF5EB92Q30503154-013F5C0A-5F23-4384-B7FA-2C375BABB7ACQ33494834-4458E562-8E02-4093-807A-26B377A3F341Q33623266-8C31D821-12EE-4456-9B0C-65CC0CF7F4EFQ33624343-BBF54276-54FE-4CAD-8BE1-B0CC151EE9D2Q33711371-BB69471C-422A-4D40-B296-022451EDB90EQ33750016-BC12AB21-8185-4FA6-A8AF-36D4C2600CFEQ33760403-15237916-5474-435C-BFD6-C1EC10FA9B78Q33767707-40176D01-E4B9-4C60-B1B9-F1E3BBA39139Q34223872-B4A0E94D-2148-42C9-AB28-46D63688C13EQ34389202-491E8B01-7BAE-4795-9B5D-AFA559A06359Q34415755-2151EEC1-90C1-4459-B635-2DFF937EDAA6Q34533728-E99DDB15-1570-4448-9F3F-A5B434C9A61AQ34625339-AF107BB8-FBBC-4F7B-9E5B-EC571DB92B60Q34626998-0B3D27DF-88B3-419D-8B1D-2A76DBFD43A0Q34694913-F02EBBC3-2663-4D95-8849-B7CB5A83D2BAQ34766657-CF066EED-AA0D-46D9-8E27-FD574D200E3EQ34794353-4F2C010C-D4FE-4E6F-942D-E3A2AB25BB34Q34998162-AF2BCF8B-9275-41C4-99EE-8240CBF19FD1Q35054508-DEAB7B9F-3784-4BE9-B9CE-73CE5EC43F9FQ35095630-53048889-3EFB-4394-981E-2949FFB213FDQ35147335-0B1494CA-6400-43BC-B589-916F6773C37EQ35176993-3D661C17-D4ED-4A71-BBA7-3946FFFCAF0CQ35566748-3EA4026C-EB04-40C5-AED7-EA8626B85C80Q35995167-9A66987A-51DC-4726-B334-B8EBB2A9D762Q36079820-98A0D898-C103-4FC7-AE33-99CA71507432Q36096978-AB89FD7F-6B2C-4D6A-A7E0-8DB601A69DA4Q36229611-D46C5651-018D-4086-9DE5-48C7E162B0ACQ36244500-78DD78C1-228B-4CAF-B35D-7DE80ECC88A7Q36288649-AC2498E8-117D-4E98-A4F5-C6311CDD59FAQ36418804-5AFFA199-63A2-4EB4-A175-55F59D50750BQ36425619-E5FC3E07-A785-4CE7-BEC0-DFE808ADF21CQ36436914-99886DAC-269C-4624-860F-021A4D27B78EQ36445933-CE4A5148-23AA-4213-87D9-0331D223B851Q36640049-4CE73382-3B50-4BA3-8747-2F691D90E03E
P2860
Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Soluble interleukin-15 recepto ...... x IL-15R alpha fusion proteins
@ast
Soluble interleukin-15 recepto ...... x IL-15R alpha fusion proteins
@en
Soluble interleukin-15 recepto ...... x IL-15R alpha fusion proteins
@en-gb
Soluble interleukin-15 recepto ...... x IL-15R alpha fusion proteins
@nl
type
label
Soluble interleukin-15 recepto ...... x IL-15R alpha fusion proteins
@ast
Soluble interleukin-15 recepto ...... x IL-15R alpha fusion proteins
@en
Soluble interleukin-15 recepto ...... x IL-15R alpha fusion proteins
@en-gb
Soluble interleukin-15 recepto ...... x IL-15R alpha fusion proteins
@nl
prefLabel
Soluble interleukin-15 recepto ...... x IL-15R alpha fusion proteins
@ast
Soluble interleukin-15 recepto ...... x IL-15R alpha fusion proteins
@en
Soluble interleukin-15 recepto ...... x IL-15R alpha fusion proteins
@en-gb
Soluble interleukin-15 recepto ...... x IL-15R alpha fusion proteins
@nl
P2093
P2860
P3181
P356
P1476
Soluble interleukin-15 recepto ...... x IL-15R alpha fusion proteins
@en
P2093
Ariane Plet
Inken Lorenzen
Joachim Grötzinger
Patricia Vusio
Yannick Jacques
Yvan Boublik
P2860
P304
P3181
P356
10.1074/JBC.M508624200
P407
P577
2005-11-11T00:00:00Z